"Our priority for 2023 remains to progress our Phase 3 vurolenatide program for short bowel syndrome including securing a clinical development and commercialization partner," commented John Temperato, President and Chief Executive Officer of 9 Meters Biopharma. "We firmly believe vurolenatide can establish a new standard of care in the treatment of short bowel syndrome with the potential to address the full SBS patient population and offer a rapid onset of action, sustained response, and a potentially convenient dosing regimen. Our Board of Directors and management team remain focused on ensuring that the Company is positioned to execute on our clinical and preclinical milestones as our financial position allows us to do so. The current financial markets, particularly for small-cap pharmaceutical companies, have been challenging in recent months; however, we are pleased to have recently strengthened our balance sheet with an equity financing and have also implemented cost-saving measures to further our cash runway. We believe that these actions align our strategic and financial goals and will help move the Company forward."
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on NMTR:
- 9 Meters Biopharma cut to Hold at Truist on cash overhang, lack of catalysts
- 9 Meters Biopharma downgraded to Hold from Buy at Truist
- 9 Meters Biopharma price target lowered to $1.70 from $2.70 at Citi
- 9 Meters Biopharma announces $5M registered direct offering priced at $1.60
- 9 Meters Biopharma confirms it doesn’t hold deposits, securities at SVB
